articleThe Lancet OncologyNov 28, 2016GREEN OA

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

EMElizabeth M. SwisherKLKevin LinAMAmit M. OzaCLClare L. ScottHGHeidi Giordano

University of Washington · Clovis Oncology (United States) · +26 more institutions

PubMed
Indexed incrossrefdatacitepubmed

Abstract

No abstract available for this paper.

Citation impact

1,197
total citations
FWCI
64.14
Percentile
100%
References
40
Citations per year

Authors

31

Topics & keywords

Topics
Keywords
  • Open label
  • Oncology
  • Medicine
  • Internal medicine
  • Ovarian carcinoma
  • Platinum
  • Ovarian cancer
  • Clinical trial
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding